Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions with permeation enhancers for drug delivery

A penetration enhancer and composition technology, applied in the direction of drug combination, drug delivery, active ingredients of heterocyclic compounds, etc.

Active Publication Date: 2018-06-08
CHILDRENS MEDICAL CENT CORP +1
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Shortcomings of current treatments for ear disorders such as middle ear infections point to need for new treatments that are non-invasive and direct acting

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions with permeation enhancers for drug delivery
  • Compositions with permeation enhancers for drug delivery
  • Compositions with permeation enhancers for drug delivery

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0555] So that the invention described herein may be more fully understood, the following examples are set forth. The examples described in this application are provided to illustrate the compounds, pharmaceutical compositions and methods provided herein and are not to be construed in any way as limiting the scope thereof.

[0556] Materials and methods

[0557] Methods and design: The experiments compared the effects of the introduction of polymer matrix and CPE on TM permeability and OM healing rate. For ex vivo experiments, a sample size of 4 for each formulation was chosen, which provided 80% power to detect 50 based on power analysis using the nonparametric Friedman test (version 7.0, nQuery Advisor, Statistical Solutions, Saugus, MA). % flux difference. A sample size of 8-10 was used for in vivo experiments, which is supported by previous publications (Pelton et al., Antimicrob. Agents Chemother. 44, 654-657 (2000)). Comparisons between positive and negative potency r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Phase transition temperatureaaaaaaaaaa
Phase transition temperatureaaaaaaaaaa
Phase transition temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition withoutthe permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment,methods of delivery, and kits for the compositions described herein are also provided.

Description

[0001] related application [0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application U.S.S.N. 62 / 201,199, filed August 5, 2015, which is incorporated herein by reference. Background technique [0003] In the United States, 12 to 16 million physician visits per year are due to otitis media (OM), making it the most common specially treated childhood illness. [1] The prevalence of acute OM (AOM) within the first 5 years of life is 90%[2], and 90% to 95% of all children in the United States suffer from at least one documented middle ear effusion by the age of 2 years . [3] 25% of all prescriptions written for children are for acute otitis media. Relapses of the disease are also notable, with one-third of all children in the United States developing six or more episodes of AOM before age seven. [4] In addition, epidemiological studies have shown that the prevalence of recurrent OM in children, especially infants, is growing. [5] The incid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/12A61K31/38A61K31/42
CPCA61K38/12A61K45/06A61K31/407A61K31/424A61K31/431A61K31/445A61K31/4709A61K31/496A61K31/5383A61K31/573A61K9/0046A61K47/06A61K47/10A61K47/20A61K47/26A61K9/06C08G79/04C08G65/3355A61K47/34A61P27/16A61P31/04A61K2300/00A61P31/00A61K31/4458A61K31/616A61K47/12A61K47/22
Inventor 丹尼尔·S·克哈奈克杨蓉莉莉·云·林
Owner CHILDRENS MEDICAL CENT CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com